4153 Reinach, ch
+41 (61) 4179660
Arpida's Extensive Presence at ICAAC Well-Received
Arpida, for the first time, had a booth which encountered significant interest among the conference attendees. Moreover, Arpida presented a total of 32 posters at ICAAC, nineteen of which were on the latestage investigational antibiotic iclaprim. One of the posters discussed detailed microbiological efficacy data from ASSIST-1, the first of two pivotal Phase III trials in complicated Skin and Skin Structure Infections. In this study iclaprim showed a high microbiological eradication rate against MRSA which was comparable to that of linezolid (84.7% versus 85.3%). Another key highlight was the poster discussing the results of a large study, investigating iclaprim’s efficacy against a panel of Staphylococcus aureus isolates from the USA and Europe. With a total of 4,516 isolates, this was one of the largest surveillance studies ever done in this area and confirmed iclaprim’s potent activity. Apart from the posters on iclaprim, Arpida presented thirteen posters on two additional compounds: AR-709 and AR-2474.
Arpida also supported a wellattended symposium at ICAAC with the title "Treatment of Methicillinresistant Staphylococcus aureus and Other Resistant Infections: An Expert Debate". In this meeting distinguished speakers such as John G. Bartlett, MD, Louis B. Rice, MD, Dennis L. Stevens, PhD, MD, Gregory J. Moran, MD, FACEP and Robert C. Moellering, Jr., MD, MACP discussed the latest trends in their field.
Dr Khalid Islam, President and CEO of Arpida Ltd., commented: "I am delighted about the large number of people showing an interest in our compounds as well as the very positive feedback that we encountered among practicing physicians and key opinion leaders. I feel this conference and the material that we’ve presented have significantly raised the awareness of iclaprim in key audiences. We very much look forward to building on this strength at the upcoming annual meeting of the Infectious Diseases Society of America (IDSA) next week in San Diego."
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.